The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results from an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

Clinical Lung Cancer

Volumn 17, Issue 3, 2016, Pages 161-168

  Gridelli, Cesare ^a   Besse, Benjamin ^b   Brahmer, Julie Renee ^c   Crinò, Lucio ^d   Felip, Enriqueta ^e   De Marinis, Filippo ^f  

^a S G MOSCATI HOSPITAL   (Italy)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Anti PD 1 antibody; Immunotherapy; Nivolumab; PD L1; Second line treatment

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; NINTEDANIB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; DRUG SAFETY; GENE MUTATION; HUMAN; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; ALGORITHM; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CONSENSUS DEVELOPMENT; EXPERT WITNESS; INTERNATIONAL COOPERATION; ITALY; LUNG NEOPLASMS; ONCOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRENDS;

ALGORITHMS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; EXPERT TESTIMONY; HUMANS; INTERNATIONAL COOPERATION; ITALY; LUNG NEOPLASMS; MEDICAL ONCOLOGY; PROGRAMMED CELL DEATH 1 RECEPTOR; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84958552083     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2016.01.004     Document Type: Review

References (36)

1. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 2015 5 29
2. R. Rosell, E. Carcereny, R. Gervais, and et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
3. C. Zhou, Y.L. Wu, G. Chen, and et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
4. T.S. Mok, Y.L. Wu, S. Thongprasert, and et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
5. L.V. Sequist, J.C. Yang, N. Yamamoto, and et al. Phase III Study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 31 2013 3327 3334
6. J.C. Yang, V. Hirsh, M. Schuler, and et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations J Clin Oncol 31 2013 3342 3350
7. A.T. Shaw, D.W. Kim, K. Nakagawa, and et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
8. A.T. Shaw, D.W. Kim, R. Mehra, and et al. Ceritinib in ALK-rearranged non-small-cell lung cancer N Engl J Med 370 2014 1189 1197
9. B. Solomon, K.D. Wilner, and A.T. Shaw Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer Clin Pharmacol Ther 95 2014 15 23
10. A. Passaro, E. Cortesi, and F. de Marinis Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors? Expert Rev Anticancer Ther 11 2011 1587 1597
11. E.B. Garon, T.E. Ciuleanu, O. Arrieta, and et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-celllung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Lancet 384 2014 665 673
12. M. Reck, R. Kaiser, A. Mellemgaard, and et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Lancet Oncol 15 2014 143 155
13. S.P. Claudia, M. Paolo, R. Antonio, and et al. New antiangiogenetic therapy beyond bevacizumab in the treatment of advanced non small cell lung cancer Curr Pharm Des 21 2015 4763 4772
14. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
15. R. Rosell, and R. Palmero PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors Cancer Biol Med 12 2015 71 73
16. R.D. Schreiber, L.J. Old, and M.J. Smyth Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 331 2011 1565 1570
17. J.R. Brahmer, and D.M. Pardoll Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer Cancer Immunol Res 1 2013 85 91
18. J.R. Brahmer Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol 41 2014 126 132
19. J.R. Brahmer, H. Hammers, and E.J. Lipson Nivolumab: targeting PD-1 to bolster antitumor immunity Future Oncol 11 2015 1307 1326
20. R.S. Herbst, J.C. Soria, M. Kowanetz, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
21. E.B. Garon, N.A. Rizvi, R. Hui, and et al. Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2015 2018 2028
22. J. Brahmer, K.L. Reckamp, P. Baas, and et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 2015 123 135
23. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
24. J.R. Brahmer, C.G. Drake, I. Wollner, and et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
25. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
26. S.N. Gettinger, L. Horn, L. Gandhi, and et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 33 2015 2004 2012
27. R. Sundar, B.C. Cho, J.R. Brahmer, and et al. Nivolumab in NSCLC: latest evidence and clinical potential Ther Adv Med Oncol 7 2015 85 96
28. H. Borghaei, L. Paz-Ares, L. Horn, and et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 2015 1627 1639
29. S.P. Patel, and R. Kurzrock PD-L1 expression as a predictive biomarker in cancer immunotherapy Mol Cancer Ther 14 2015 847 856
30. S. Gettinger, L. Horn, S.J. Antonia, and et al. Efficacy of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with previously treated advanced non-small cell lung cancer (NSCLC): subpopulation response analysis in a phase 1 trial J Thorac Oncol 8 2013 P2.11-038
31. E.A. Akbay, S. Koyama, J. Carretero, and et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors Cancer Discov 3 2013 1355 1363
32. A. D'Incecco, M. Andreozzi, V. Ludovini, and et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients Br J Cancer 112 2015 95 102
33. M. Ji, Y. Liu, Q. Li, and et al. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation J Transl Med 13 2015 5
34. M. Reck, R. Kaiser, A. Mellemgaard, and et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Lancet 15 2014 143 155
35. E.B. Garon, T.E. Ciuleanu, O. Arrieta, and et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Lancet 384 2014 665 673
36. R.S. Herbst, P. Baas, D.W. Kim, and et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Lancet 2015 10.1016/S0140-6736(15)01281-7 [Epub ahead of print]